What’s next for the nuclear medicine technology industry

By now, you probably know that the U.S. is set to enter the final phase of a two-year moratorium on new nuclear weapons development, the first such phase since the U,S.

left the Nuclear Nonproliferation Treaty in 1993.

While this moratorium is largely symbolic, it also has an enormous impact on how we manage our nuclear weapons arsenal, and its effect on the U to which we are committed.

In this series, we will look at some of the technologies that are in development and the opportunities that exist for the industry.

The Nuclear Medicine Technologist (NMT) is a graduate of MIT’s Sloan School of Management and holds a PhD in nuclear medicine.

She’s a member of the Nuclear Medicine Advisory Board and the Nuclear Engineering and Nuclear Technology Advisory Board.

In 2018, she joined a group of industry experts, led by her husband, Dr. Mark Boulware, to develop a framework for future nuclear medicine research.

This article originally appeared on The Conversation.

Follow us on Facebook and Twitter to receive our top stories each day.

Read next: US to cut nuclear weapons research, halt new research into new nuclear medicine technologies